The Swedish BioFINDER - Preclinical AD Study
This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.
• Age 50-80
• Individuals aged 50-60 require at least one of the following risk factors for AD:
‣ Known APOE-E4 carrier
⁃ Known 1st degree family history of dementia or severe memory loss with onset prior to 75.
⁃ Known amyloid brain pathology by either CSF or PET scan.
• Mini-Mental State Examination (MMSE) ≥26 (aged \>65); MMSE ≥27 (aged 50-65).
• Score of 12 or above on the Montreal Cognitive Assessment (MoCA) telephone version.
• Speaks and understands Swedish to the extent that an interpreter is not necessary to fully understand the study information and cognitive tests.
∙ 6a. Preclinical AD subgroup (n=450): Amyloid pathology according to CSF AD biomarkers and Aβ-PET scans.
∙ 6b. Non-Preclinical AD subgroup (n=150): No sign of preclinical AD using CSF AD biomarkers or Aβ-PET scans.